European Annals of Allergy and Clinical Immunology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Dupilumab in patients with atopic dermatitis: assessing treatment response, clinical features and potential biomarkers in real-life
Conclusions. In this cohort, none of the evaluated biomarkers at baseline were associated with a better/earlier clinical response to dupilumab. Dupilumab treatment for 52 weeks resulted in a significant and sustained reduction in blood levels of total IgE and allergen-specific IgE to aeroallergens. The potential long-term clinical benefit of these effects, even after discontinuing dupilumab therapy in patients with AD, should be explored to a greater extent.PMID:38591168 | DOI:10.23822/EurAnnACI.1764-1489.341 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - April 9, 2024 Category: Allergy & Immunology Authors: R Lim ão R Br ás E Pedro S L Silva A Lopes Source Type: research